touchOPHTHALMOLOGY touchOPHTHALMOLOGY
Corneal and External Disorders
Read Time: 2 mins

Foreword – US Ophthalmic Review, 2013;6(2):76

Copy Link
Published Online: Oct 24th 2013 US Ophthalmic Review, 2013;6(2):76
Authors: Bruce E Spivey
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

This issue of US Ophthalmic Review covers a diverse range of topics across different parts of the eye, offering something for all readers with various ophthalmic interests. It begins with a review of a common ocular allergy—allergic conjunctivitis—which is a significant ophthalmic burden throughout the world. It is estimated that up to 40 % of people in some populations have experienced it during their lives. Ophthalmologists routinely encounter it, but effective management can be challenging. The discussion by Gong and Blaiss of the traditional steroid treatments and the development of a new treatment, loteprednol etabonate, is therefore timely and of considerable interest.

Article:

Ocular rosacea is a disease of unknown aetiology that despite its high prevalence and potential to cause vision loss, remains untreatable. Wladis and Adam discuss laser and surgical treatments of this disease and consider the current knowledge of cellular and molecular biologic mechanisms involved and how these may lead to new, much-needed therapeutic approaches. This issue also covers advances in cataract surgery in both femtosecond methods used in adults and, remarkably, in surgical interventions to improve visual outcomes in extremely premature babies as discussed by Astle et al. Moving further into the eye, age-related macular degeneration (AMD) is an increasingly common condition in aging populations and effective treatments remain a substantially unmet need. The promising antiangiogenic potential of the plant extract resveratrol is discussed in an article by Jarratt et al. In addition, the intriguing possible link between aspirin usage and AMD as raised in case reports and observational studies is discussed by Christen and Chew. The association with aspirin is compelling, but randomized trials are needed to confirm the increased AMD risk.

Another common ophthalmic condition is branch retinal vein occlusion, which is a significant cause of macular edema worldwide. Sophie and Campochiaro consider the use of monoclonal antibody and laser treatments in the management of this disease. Finally, Bitner and Stone consider current and emerging topical therapies in ocular surface tumour treatment. These tumours were previously treated surgically, but the availability of topical treatments has substantially altered the options available in this disease and outcomes have improved.

We hope you find the articles in this issue useful and that they provide helpful information and discussions that are relevant to your ophthalmic practice and interests.

US Ophthalmic Review would like to take this opportunity to thank all participants on this edition, from organisations to individuals. A special thanks goes to our editorial board for their continuing support and invaluable guidance and the biggest thanks are reserved for the expert authors, who spared precious time and effort to produce a perceptive selection of articles. This expert discussion and the wide variety of topics covered ensure there is much of interest for every reader and we hope you find this edition as useful and insightful as those before it.

Further Resources

Share this Article
Related Content In Corneal and External Disorders
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72